2023
Adapting psychedelic medicine for headache and chronic pain disorders
Schindler E, Hendricks P. Adapting psychedelic medicine for headache and chronic pain disorders. Expert Review Of Neurotherapeutics 2023, 23: 867-882. PMID: 37652000, DOI: 10.1080/14737175.2023.2246655.Peer-Reviewed Original ResearchConceptsChronic pain disordersPain disordersHeadache disordersChronic pain patientsRecent case reportsDifferent treatment paradigmsPsychedelic medicineSubstance use disordersMechanism of actionPain patientsChronic painCase reportClinical trialsTreatment paradigmTreatment outcomesTherapeutic effectLarge dosesUse disordersAdjunctive psychotherapyTherapeutic outcomesHeadacheBeneficial effectsSubjective effectsBranches of medicineDisorders
2011
Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD)
Schindler EA, Dave KD, Smolock EM, Aloyo VJ, Harvey JA. Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Pharmacology Biochemistry And Behavior 2011, 101: 69-76. PMID: 22197710, PMCID: PMC3272148, DOI: 10.1016/j.pbb.2011.12.002.Peer-Reviewed Original ResearchConceptsHead-bobbing behaviourLysergic acid diethylamideReceptor antagonistEx vivoDimethoxy-4Acute drug injectionAcid diethylamideChronic drug treatmentBehavioral pharmacologyMechanism of actionReceptor binding propertiesDrug injectionDrug treatmentAnimal modelsReceptor activationBehavioral effectsClinical literatureReceptorsAntagonist ligandsNaïve rabbitsPharmacologyHallucinogensAntagonistAminopropaneVivo